The blood–brain barrier (BBB) represents one of the most critical and complex obstacles in brain cancer research and therapeutic development. Its highly selective nature protects the brain, yet simultaneously limits the effectiveness of many promising treatments. Overcoming this challenge requires not only innovative biology, but also predictive, physiologically relevant pre‑clinical models.

In this joint webinar by Dynamic42 and EPO Experimental Pharmacology & Oncology Berlin‑Buch GmbH, we explore how advanced BBB‑on‑Chip technology is opening new avenues for understanding brain tumors, brain metastasis, and drug transport into the brain.

PhD researchers Amélie Paillereau (Dynamic42) and Michelle Zimmer (EPO) will share first‑hand insights from their research, highlighting how BBB‑on‑Chip models are being established, optimized, and applied to investigate gliomas, and other brain tumor entities. Their presentations will be followed by an in‑depth expert discussion and panel round with Dr. Thomas Sommermann, Dr. Martin Raasch, and Dr. Jens Hoffmann, addressing current bottlenecks in brain cancer research and the growing importance of advanced preclinical systems for translational success.

Key topics covered in this webinar

• Fundamental research on the blood–brain barrier
• Establishment of advanced BBB‑on‑Chip models
• Modeling brain tumor interactions with the BBB
• Drug transport and efficacy testing
• Assessing drug efficacy against brain tumors in a physiologically relevant setting
• Emerging directions and future developments

This webinar is designed for researchers and decision‑makers in oncology, neuroscience, pharmacology, and preclinical model development who want to gain practical insights into state‑of‑the‑art BBB modeling and its role in advancing brain cancer research.